Emerging treatments

Palopegteriparatide

Palopegteriparatide, a prodrug consisting of PTH (1‐34) conjugated to a methoxypolyethylene glycol carrier, is approved in the US and Europe for the treatment of hypoparathyroidism in adults. In one phase 3 randomized, double-blind, placebo-controlled, 26-week trial of adults with chronic hypoparathyroidism, 79% (48/61) of participants receiving palopegteriparatide, compared with 5% (1/21) receiving placebo, achieved the composite primary endpoint (i.e., maintenance of normocalcemia, independence from active vitamin D and high-dose calcium, and no increase in the prescribed study drug over the final 4 weeks of the blinded period).[37]

Teriparatide

Teriparatide, a human recombinant PTH (1-34), has been evaluated in small studies of patients with hypoparathyroidism.​[38][39][40]​​​​​​ Teriparatide is approved for use in osteoporosis, but not hypoparathyroidism.

Use of this content is subject to our disclaimer